| Document |
Document Title |
|
WO/2024/031002A1 |
This disclosure includes pesticidal compounds, compositions, and related agricultural methods.
|
|
WO/2023/196340A1 |
Compositions capable of promoting mitofusin activation may include a mitofusin activator having a structure represented by (I) any stereoisomer thereof, or any pharmaceutically acceptable salt thereof. G is N or CH, and A is an optionall...
|
|
WO/2023/170715A1 |
The present disclosure provides a compound of Formula (I), its analogs, tautomeric forms, stereoisomers, enantiomers, diastereomers and pharmaceutically acceptable salts thereof. The present disclosure also provides a process for prepari...
|
|
WO/2023/135341A1 |
The invention relates to a urease inhibiting composition containing at least one of the compounds of formulas (I), (II) and (III) or a combination thereof: 1,4-dihydroxy-3,6-diisobutylpiperazine-2,5-dione (I), 2-[(N-hydroxyleucyl)-imino]...
|
|
WO/2023/106377A1 |
Provided is a method for producing a blocked isocyanate compound, the method comprising a reaction step of reacting a primary amine compound, a carbonic acid derivative, and a blocking agent by means of heat treatment in the presence of ...
|
|
WO/2023/044343A1 |
The present disclosure details various lipids, compositions, and/or methods of optimized systems and delivery vehicles for the delivery of nucleic acid sequences, polypeptides or peptides for use in vaccinating against infectious agents.
|
|
WO/2023/010107A1 |
A method of treating cancer includes a combination of a therapeutically effective amount of an illudin or an illudin analog thereof, derivative, or a pharmaceutically acceptable salt thereof; and a therapeutically effective amount of a s...
|
|
WO/2022/167926A1 |
The method (100) and a reactor assembly (200) for the synthesis of Methoxy amine hydrochloride (MAHCl) is disclosed. Methoxy amine hydrochloride is a primary reagent used for preparation of one or more oxime derivatives. The present disc...
|
|
WO/2022/156391A1 |
The present invention relates to the technical field of chemical engineering, and specifically relates to a preparation method for a core-shell titanium-silicon molecular sieve coated zinc-cadmium alloy particle catalyst and a method for...
|
|
WO/2022/146324A1 |
This invention relates to the synthesis of pyrimidine-4 (1H)-one derivatives from Meldrum's acid, carbonyl compounds (aldehyde/ketone), and guanylhydrazone derivatives and tautomers, enantiomers, and salts thereof.
|
|
WO/2022/048025A1 |
The present invention provides a method for synthesizing an atorvastatin calcium intermediate by using a multi-component one-pot method. Specifically, the present invention provides a one-pot synthesis method for 4-(4-fluorophenyl)-2-(2-...
|
|
WO/2021/110445A1 |
The present invention relates to a process for purification of a mixture comprising water, N-alkyl-hydroxylammonium salts and some byproducts wherein from the mixture water and byproducts are distilled off until the purity of N-alkyl-hyd...
|
|
WO/2021/104199A1 |
Provided are synthetic small molecules and their use as drug, in particular in the treatment of cancer. Also provided is a method of inhibiting cancer stem cells. Also provided is a method for treatment of cancers and other diseases by a...
|
|
WO/2020/094527A1 |
The present invention relates to a novel process for the iridium-catalysed hydrogenation of oximes. The invention also relates to novel iridium catalysts for use in the iridium-catalysed hydrogenation of oximes and to processes of prepar...
|
|
WO/2020/094528A1 |
The present invention relates to novel processes for the enantioselective iridium-catalysed hydrogenation of oximes and oxime ethers to provide compounds of formula (II) and salts thereof formula (I) and (II).
|
|
WO/2020/081414A1 |
Methods for determining the likelihood that a subject suffering from a solid tumor cancer will benefit from treatment with an illudin are disclosed herein. Further, there are also methods for treatment based on such determination. In sev...
|
|
WO/2020/043747A1 |
The present invention relates to linker molecules of formula (1), X-Tb-Va-U-Y-Z (1) and a method for purifying peptides using said linker molecules. The linker molecule can be coupled to a purification resin via the moiety X and to a pep...
|
|
WO/2020/014606A1 |
Described are compositions and methods for inhibiting polymerization of a monomer (e.g., styrene) composition a quinone methide polymerization retarder and an oxygen-containing amine compound that is a tertiary amine or hydroxylamine. In...
|
|
WO/2019/246119A1 |
The present disclosure provides method of treating or preventing a microbial infection caused by a prokaryotic pathogen in a subject, the method comprising administering a compound of Formula (I) as set forth in the specification. In one...
|
|
WO/2019/202262A2 |
The present invention relates to a new family of alkoxyamines offering better storage stability, especially in the presence of monomers and/or a solvent. In particular, the present invention relates to a new family of oligomeric alkoxyam...
|
|
WO/2019/051198A1 |
Indoleamine 2,3-dioxygenase-1 prodrugs and methods of use thereof are disclosed.
|
|
WO/2018/202525A1 |
The invention is in the technical field of insect control and relates to novel phenoxyethanamine derivatives, their production and use for controlling pests and in particular insecticide-resistant pests such as mosquitoes and cockroaches.
|
|
WO/2018/199146A1 |
Provided is a novel method for producing amide compounds at high stereochemical selectivity. This method for producing amide compounds is provided with an amidation step for reacting an aminoester compound represented by general formula ...
|
|
WO/2018/106221A1 |
Sulfide scavengers useful to reduce sulfide concentration in fluid streams and methods of using these scavengers. The scavengers comprise oil soluble reaction products of formaldehyde/N-substituted hydroxylamines and can be used to reduc...
|
|
WO/2018/094334A1 |
Prodrugs of hydroxamate-based GCPII inhibitors and methods of their use for treating a disease or condition are disclosed.
|
|
WO/2018/060354A1 |
The present invention relates to compounds of formula (I) and to pharmaceutical compositions containing them, wherein meanings of the substituents are indicated in the description. Such compounds for use in the treatment of cancer and ot...
|
|
WO/2017/170885A1 |
Crystals of (2S)-2-((4-((4-((1S)-1,2-dihydroxyethyl)phenyl)ethynyl)benzo
yl)(methyl)amino)-N-hydroxy-N',2-dimethylmalonamide having diffraction peaks at diffraction angles (2θ) of 3.8±0.2°, 7.7±0.2°, and 10.8±0.2°, and the like or...
|
|
WO/2017/154019A1 |
The present invention relates to an improved process for the preparation of 1,3-bis(2-chloroethyl)-1 -nitrosourea compound of formual-1 which is represented by the following structural formula:
|
|
WO/2017/106520A1 |
Disclosed are compounds of formulas I and II, in which R, R0, R1-R4, R7-R10, n, X, Y, Y', and E are as described herein, pharmaceutical compositions containing such compounds. The compounds and pharmaceutical compositions are for use in ...
|
|
WO/2017/024009A1 |
β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and...
|
|
WO/2017/012757A1 |
The invention relates to an improved method for the preparation of alkylsalicylaldehyde or its corresponding metallic salts. The invention also relates to a method for the preparation of alkylsalicylaldoxime by reacting said alkylsalicyl...
|
|
WO/2017/006295A1 |
Disclosed are compounds having the formula: (I) wherein R1, R2 and R3 are as defined herein, and methods of making and using the same, including use as inhibitors of BMP1, TLL1 and/or TLL2 and in treatment of diseases associated with BMP...
|
|
WO/2016/043001A1 |
Provided is a novel compound used in solar cells. This compound is an organic/inorganic mixed compound indicated by formula (I). R1Y1N+H2(Y2H)M1X1 3 … (I) (In the formula (I): R1 indicates a C1-C6 alkyl group, a C3-C6 alkenyl group, or...
|
|
WO/2016/023510A1 |
Provided is a micromolecule compound as represented by structural formula (I). The product of the present invention in various concentrations and dosages can achieve an obvious change in the growth period of hairs, promoting the growth o...
|
|
WO/2015/199367A1 |
An aspect of the present invention provides a styrenated phenol compound characterized in that styrenated phenol is combined with a hydrazine or diaminoalkane compound. The styrenated phenol compound prevents discoloration in the use wit...
|
|
WO/2015/141956A1 |
A precursor compound, according to one embodiment of the present invention, is represented by R1(C6H5)NSiH3, wherein R1 is any one selected from a halide group, hydrogen, a C1-C4 alkyl group, a C4-C7 cyclic alkyl group, a phenyl group or...
|
|
WO/2015/117146A1 |
β-Substituted -amino acids, β-substituted γ-amino acid derivatives, and β-substituted γ-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted γ-amino acid derivatives and Î...
|
|
WO/2015/114031A1 |
The present invention relates to primary hydroxylamines, to pharmaceutical compositions comprising them, to their use in the treatment and/or prevention of bacterial infections and to their use in the prevention of formation or reduction...
|
|
WO/2015/117147A1 |
β-Substituted β-amino acids, β-substituted β-amino acid derivatives, and β-substituted β-amino acid analogs and (bio)isosteres and their use as chemotherapeutic agents are disclosed. The β-substituted β-amino acid derivatives and...
|
|
WO/2015/080936A1 |
The disclosure provides improved processes for preparing N-methylhydroxylamine and N-methylhydroxylamine hydrochloride.
|
|
WO/2015/061630A2 |
A compound is provided, comprising: an Fe(III)-binding or an Fe(III)-bound siderophore; one or more optional linker covalently bound to the siderophore; a drug; and an Fe(III) to Fe(II) reduction triggered linker bound to the drug and th...
|
|
WO/2015/019928A1 |
The present invention relates to a novel synthesis method that is capable of producing an optically active binaphthyldiamine derivative, under conditions whereby the binaphthyldiamine derivative can be produced more safely and efficientl...
|
|
WO/2015/001436A1 |
The present invention relates to alkoxyamines of general formula (I), and to compounds of general formula (lla), (lIb), (lIc), (IId), IIe), (Ilf) or (Ilg), as such and for the treatment of cancers.
|
|
WO/2014/206855A1 |
The present invention relates to a process for the enantioselective preparation of the compound of formula (lb), which process comprises a) reducing the (E)- or (Z)-form of a compound of formula (II), with an enantioselective reagent to ...
|
|
WO/2014/207071A1 |
The present invention relates to novel strobilurine type compounds, to compositions comprising at least one such compound, to methods for combating phytopathogenic fungi, to the use of such compounds and to seeds coated with at least one...
|
|
WO/2014/197991A1 |
The present application describes amphiphatic compounds like compound Ila below, compositions and methods for incorporating chemoselective and bio-orthogonal complementary functional groups into liposomes. Such compounds are incorporated...
|
|
WO/2014/159508A1 |
The present disclosure provides methods for separating ketones and alcohols. In one embodiment, the methods and compositions disclosed are useful in separating cyclohexanol from cyclohexanone. In one embodiment, cyclohexanone is converte...
|
|
WO/2014/064706A1 |
Provided herein are novel, commercially viable and industrially advantageous processes for the preparation of Agomelatine or a salt thereof, in high yield and purity, using novel intermediates.
|
|
WO/2013/120874A1 |
The present application relates to a process for preparing chloroamines which can be used as precursors for syntheses of fine chemicals and active ingredients from pharmaceuticals and/or agriculture, by reaction of secondary amines of th...
|
|
WO/2013/104774A1 |
The present invention relates to the preparation of optically resolved chiral compounds of β-amino acid type active pharmaceutical ingredients (API), more specifically to β-aminobutyryl substituted compounds and especially β-aminobuty...
|
